11th ASM Conference on Candida and candidiasis

产品说明： 念珠菌是人类的主要真菌病原体，引起的疾病范围从口腔和阴道念珠菌病到危及生命的念珠菌血症和侵袭性疾病。念珠菌领域的重点是广泛的主题，涉及流行病学，耐药性，感染，宿主反应，疫苗和治疗。念珠菌和念珠菌病会议每两年举行一次，是介绍这些不同领域的前沿进展和最新观点的首要论坛。请求提供资金，为将于2012年3月29日至4月2日在加利福尼亚州旧金山弗朗西斯科举行的第十一届念珠菌和念珠菌病会议提供部分支助。会议将由美国微生物学会主办，该学会将提供管理专业知识和财政支持。该计划将基于该系列的过去会议，这些会议吸引了450多名美国和国际科学家的出席，并在参与者调查中得到了热情的支持。该计划将包括38位发言人，他们将根据基础和/或临床真菌学的专业知识进行选择，48位发言人将根据提交的摘要进行选择。这一安排将提供灵活性，以介绍最先进的进展，并争取各种新兴和成熟的社区成员作为发言者。将有关于念珠菌病的流行病学，诊断和治疗的临床讲座，演讲者经过精心筛选，以确保和蔼可亲和有效性。这些会谈将 将被纳入会议，重点是念珠菌感染的各个关键方面，包括环境信号，系统生物学，抗真菌剂和耐药性，免疫识别，疫苗，形态发生和生物膜。将有两个午餐会议，其中各种实验啮齿动物模型的念珠菌病的优势和弱点将讨论双方的基础科学家和临床医生。此外，还将同时举行真菌代谢、新技术、表观遗传学和细胞凋亡的会议，以进一步鼓励富有成效的互动和讨论。每天下午，将有一个海报会议，使总共250-300海报将提交。我们有信心，我们的目标-提出最新的 将实现以下目标：促进该领域的进步，突出青年科学家（特别是妇女和少数民族）的成就，促进协同和跨学科的互动，并为全社会的讨论提供场所。 公共卫生相关性： 念珠菌是引起感染性疾病的主要真菌，影响艾滋病患者、癌症化疗患者、早产儿和许多其他人。第12届念珠菌和念珠菌病会议将为念珠菌研究界提供一个论坛，介绍最新的进展和想法，涵盖从临床问题到分子机制的广泛主题，从真菌的生长到宿主的反应。会议将有助于规划未来研究的进程，并促进了解，治疗和预防疾病的迫切需要。

DESCRIPTION: Candida is the major fungal pathogen of humans, causing diseases that range from oral and vaginal candidiasis to life-threatening candidemia and invasive disease. The Candida field focuses on a broad spectrum of subjects that relate to epidemiology, drug resistance, infection, host response, vaccines and therapeutics. The Candida and Candidiasis Conference, held every two years, is the premier forum for the presentation of cutting-edge advances and the latest perspectives in these diverse areas. Funds are requested to provide partial support for the 11th Conference on Candida and Candidiasis, which will be held from March 29 to April 2, 2012, in San Francisco, CA. The conference will be sponsored by the American Society for Microbiology, which will provide both management expertise and financial support. The program will be based upon past conferences of the series, which have reliably drawn attendance of over 450 American and International scientists, and have been met with enthusiastic support in participant surveys. This program will include 38 speakers who will be chosen for their expertise in fundamental and/or clinical mycology and 48 speakers who will be selected based on submitted abstracts. This arrangement will provide the flexibility to present cutting-edge advances and to enlist a diverse spectrum of emerging and established community members as speakers. There will be clinical talks about the epidemiology, diagnosis, and treatment of candidiasis, with speakers carefully prescreened for affability and effectiveness. These talks will be incorporated into sessions that focus on various key aspects of candidal infections, including environmental signaling, systems biology, antifungal agents and resistance, immune recognition, vaccines, morphogenesis, and biofilms. There will be two lunch sessions in which the strengths and weakness of various experimental rodent models of candidiasis will be discussed by both basic scientists and clinicians. In addition, there will be concurrent sessions on fungal metabolism, new technologies, epigenetics, and apoptosis to further encourage productive interaction and discussion. Each afternoon, there will be a poster session so that a total of 250-300 posters will be presented. We are confident that our goals - to present the latest advances in the field, to spotlight achievements of junior scientists (especially women and minorities), to promote synergistic and interdisciplinary interactions, and to provide a venue for community-wide discussion - will be achieved. PUBLIC HEALTH RELEVANCE: Candida is the major fungus that causes infectious disease, affecting AIDS patients, cancer chemotherapy patients, premature infants, and many others. The 12th Conference on Candida and Candidiasis will provide a forum for the Candida research community to present the most recent advances and ideas, covering a broad spectrum of subjects from clinical issues to molecular mechanisms, from growth of the fungus to response of the host. The conference will help chart the course of future research and facilitate the urgent necessity to understand, treat, and prevent disease.